A Single-center, Double-blind Placebo-controlled Parallel Group Phase II Study of the Efficacy and Safety of Rilonacept in Subjects With Cold Contact Urticaria (CCU)
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Rilonacept (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Acronyms Cures
- 05 Jan 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 05 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.
- 28 Jan 2016 Planned End Date changed from 1 May 2015 to 1 Apr 2017, according to ClinicalTrials.gov record.